What it's for (Indications)
- Cimetidine, available under brand names such as Tagamet, is a histamine H2-receptor antagonist indicated for the short-term treatment and maintenance therapy of active duodenal ulcers, typically for durations of up to eight weeks.
- It is also extensively utilized for the management of active benign gastric ulcers, where its acid-reducing properties facilitate healing.
- A primary application includes the treatment of gastroesophageal reflux disease (GERD), providing effective relief from symptoms such as heartburn, acid indigestion, and sour stomach, and promoting the healing of erosive esophagitis associated with GERD.
- Furthermore, cimetidine is a well-established therapeutic agent for the long-term management of pathological hypersecretory conditions, most notably Zollinger-Ellison syndrome, where it effectively controls excessive gastric acid production.
- In some clinical settings, it may also be employed for the prevention of stress ulcers in critically ill patients, although other agents are often preferred in contemporary practice.
- The therapeutic efficacy is directly attributable to its ability to significantly decrease both basal and stimulated gastric acid output.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cimetidine is highly individualized based on the specific indication, the patient's renal function, and the overall clinical response to therapy. For the treatment of active duodenal ulcers, a common adult oral dosage is 800 mg once daily at bedtime or 300 mg four times daily with meals and at bedtime, typically administered for a duration of 4 to 8 weeks. For maintenance therapy to prevent recurrence of duodenal ulcers, 400 mg once daily at bedtime is frequently prescribed. In cases of active benign gastric ulcers, the recommended adult oral dosage is usually 300 mg four times daily or 800 mg once daily at bedtime for 6 to 8 weeks. For gastroesophageal reflux disease (GERD) and erosive esophagitis, dosages such as 800 mg twice daily or 400 mg four times daily may be employed for 6 to 12 weeks to facilitate healing. For pathological hypersecretory conditions, including Zollinger-Ellison syndrome, the initial adult oral dosage is typically 300 mg four times daily, with subsequent adjustments made based on gastric acid output and clinical response, often requiring substantially higher doses. For patients with impaired renal function (creatinine clearance less than 30 mL/min), the dosage should be significantly reduced, commonly to 300 mg every 12 hours, with further titration based on clinical effect and tolerability. Intravenous administration is available for severe conditions or when oral intake is not feasible. |
Safety & Warnings
Common Side Effects
- Cimetidine is generally considered well-tolerated, but it can elicit a range of adverse effects that vary in incidence and severity.
- Common side effects often include central nervous system manifestations such as headache, dizziness, and drowsiness, as well as gastrointestinal disturbances like diarrhea and constipation.
- Less frequently, but of significant clinical concern, are more pronounced central nervous system (CNS) disturbances, particularly in elderly patients and those with pre-existing renal or hepatic impairment, which can manifest as confusion, agitation, hallucinations, delirium, or slurred speech; these effects are typically reversible upon discontinuation of the drug.
- Endocrine effects, including gynecomastia (breast enlargement) in men and galactorrhea in women, along with impotence, have been reported, primarily with long-term use and higher doses, attributed to cimetidine's weak anti-androgenic properties.
- Hematologic abnormalities, though rare, can include thrombocytopenia, leukopenia, and agranulocytosis.
- Hepatic effects, such as reversible increases in serum transaminases and bilirubin, and rare cases of hepatitis, have been observed.
- Cardiovascular effects, including bradycardia or tachycardia, have been reported, predominantly with rapid intravenous administration.
- Hypersensitivity reactions, encompassing rash, fever, and anaphylaxis, are also potential adverse events.
Serious Warnings
- Black Box Warning: Cimetidine does not carry a formal FDA-mandated Black Box Warning. However, healthcare professionals and patients must be acutely aware of several significant safety concerns that necessitate careful consideration during its prescription and use. Foremost among these is the potential for profound and clinically significant drug interactions due to cimetidine's robust inhibition of multiple cytochrome P450 enzymes (specifically CYP1A2, CYP2C9, CYP2D6, and CYP3A4). This can lead to elevated plasma concentrations and increased toxicity of numerous co-administered medications, including but not limited to warfarin (increased bleeding risk), phenytoin, theophylline, lidocaine, certain benzodiazepines, and tricyclic antidepressants. Close monitoring of drug levels and appropriate dose adjustments of these co-prescribed drugs are critical to prevent adverse outcomes. Furthermore, central nervous system (CNS) adverse effects, such as confusion, disorientation, hallucinations, delirium, and slurred speech, are more prevalent and severe in elderly patients and those with pre-existing renal or hepatic impairment. These neurological disturbances, although typically reversible upon discontinuation of cimetidine, can be significant and debilitating. Lastly, the symptomatic relief afforded by cimetidine does not preclude the presence of underlying gastric malignancy; therefore, appropriate diagnostic studies should be performed in patients presenting with dyspepsia, especially in older individuals or those with alarm symptoms (e.g., dysphagia, weight loss, persistent vomiting), before initiating or continuing cimetidine therapy.
- Several critical warnings and precautions are associated with cimetidine use to ensure patient safety and optimize therapeutic outcomes.
- As detailed in the 'Black Box Warning' section, cimetidine is a potent inhibitor of various cytochrome P450 enzymes (e.
- g.
- , CYP1A2, CYP2C9, CYP2D6, CYP3A4), leading to significant drug-drug interactions with medications that are metabolized by these pathways, such as warfarin, phenytoin, theophylline, and certain tricyclic antidepressants.
- Careful therapeutic monitoring and appropriate dose adjustments are essential when these drugs are co-administered to avoid increased plasma concentrations and potential toxicity of the co-medications.
- The symptomatic improvement observed with cimetidine therapy does not preclude the presence of gastric malignancy; thus, appropriate diagnostic evaluation, including endoscopy, should be performed in patients presenting with gastric ulcer symptoms, especially in older individuals or those with alarm symptoms, before initiating therapy.
- Dosage adjustments are mandatory in patients with impaired renal function due to decreased cimetidine clearance, which can lead to increased plasma levels and a higher risk of adverse effects, particularly central nervous system disturbances.
- Caution is also advised in patients with pre-existing hepatic impairment.
- Although generally categorized as Pregnancy Category B, cimetidine should only be used during pregnancy if clearly needed, and it is excreted into breast milk, necessitating caution and potential cessation of breastfeeding during treatment.
How it Works (Mechanism of Action)
Cimetidine functions as a highly selective competitive antagonist of histamine at the histamine H2-receptors located on the gastric parietal cells. By binding to these receptors, cimetidine effectively blocks the stimulatory action of histamine, which is a key physiological mediator of gastric acid secretion. This blockade results in a significant and dose-dependent reduction in both basal (unstimulated) and stimulated gastric acid output. Specifically, cimetidine inhibits acid secretion stimulated by various agonists including histamine, gastrin, and acetylcholine. It reduces the volume of gastric juice, the concentration of hydrogen ions, and, consequently, the total acid output. This mechanism allows cimetidine to decrease the acidity within the stomach and duodenum, thereby promoting the healing of ulcers and alleviating symptoms associated with hypersecretory conditions and gastroesophageal reflux disease (GERD). Its action is reversible and typically achieves maximal inhibition of acid secretion within a few hours of administration, providing sustained relief.